Gemcitabine as single agent in pretreated T-cell lymphoma patients: Evaluation of the long-term outcome

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 860-863

  Zinzani, P L ^a   Venturini, F ^a   Stefoni, V ^a   Fina, M ^a   Pellegrini, C ^a   Derenzini, E ^a   Gandolfi, L ^a   Broccoli, A ^a   Argnani, L ^a   Quirini, F ^a   Pileri, S ^a   Baccarani, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chemotherapy; Gemcitabine; Mycosis fungoides; Peripheral T Cell lymphomas; Radiotherapy

Indexed keywords

GEMCITABINE;

ADULT; AGED; ALOPECIA; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DISEASE FREE INTERVAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 77951964918     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp508     Document Type: Article

References (32)

1. Coiffier B, Brousse N, Peuchmaur M et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphoma. A prospective study of 361 immunophenotyped patients treated with LNH-84 regimen. Ann Oncol 1990; 1: 45-50.
2. Lippman SM, Miller TP, Spier CM et al. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood 1988; 72: 436-441.
3. Armitage JO, Vose JM, Linder J et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol 1989; 7: 1783-1790
4. Reiser M, Josting A, Soltani M et al. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 2002; 43: 805-811.
5. Siegert W, Agthe A, Griesser H et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen: a multi-center study. Kiel Lymphoma Study Group. Ann Intern Med 1992; 117: 364-370.
6. Evens AM, Gartenshaus RB. Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol 2004; 5: 289-303.
7. Siegel RS, Pandolfino T, Guitart J et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18: 2908-2925.
8. Whittaker SJ, Marsden JR, Spittle M et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous, T-cell lymphomas. Br J Dermatol 2003; 149: 1095-1107.
9. Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-1030.
10. Zinzani PL, Baliva G, Magagnoli M et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18: 2603-2606.
11. Zinzani PL, Magagnoli M, Bendandi M et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998; 9: 1351-1353.
12. Sallah S, Wehbie R, Lepera P et al. The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia. Br J Haematol 1999; 104: 163-165.
13. Duvic M, Talpur R, Wen S et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006; 7: 51-58
14. Marchi E, Alinari L, Tani M et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104: 2437-2441.
15. Arkenau HT, Chong G, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 2007; 92: 271-272.
16. Emmanouilides C, Colovos C, Pinter-Brown L et al. Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 2004; 5: 45-49.
17. Ng M, Waters J, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005; 92: 1352-1357.
18. Crump M, Shepherd L, Lin B et al. A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-cell and T-cell nonHodgkin's lymphoma. Clin Lymphoma 2005; 6: 56-60.
19. Harris N, Jaffe E, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
20. Sobin LH, Hermanek P, Hutter RV. TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer 1988; 61: 2310-2314.
21. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
22. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
23. Toner LE, Vrhovac R, Smith EA et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 924-932.
24. Gallamini A, Zaja F, Patti C et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316-2323.
25. Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764-2769.
26. Casale DA, Bartlett NL, Hurd DD et al. A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia. Blood 2006; 108: 771a (Abstr 2727).
27. d'Amore F, Radford J, Jerkeman M et al. Zanolimumab (HuMax-CD4AdvPSSym.-1.C228), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma. Blood 2007; 110: 999a (Abstr 3409).
28. Zinzani PL, Musuraca G, Tani M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 4293-4297.
29. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115.
30. Bates S, Piekarz R, Wright J et al. Final clinical results of a phase 2 NCI multicenter study or romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included). Blood 2008; 112: 556 (Abstr 1568).
31. Horwitz S, Duvic M, Kim Y et al. Low-dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: preliminary results of a multicenter dose finding trial. Ann Oncol 2008; 19: 162 (Abstr 261).
32. O'Connor OA, Pro B, Pinter-Brown L et al. PROPEL: a multi-center phase 2 openlabel study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma. Blood 2008; 112: 103 (Abstr 261).